Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024

See original here:
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy...

TURKU, Finland and BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces the nomination of its co-founders, Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, as finalists in the ‘SMEs’ category of the European Inventor Award 2024.

More here:
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

BEVERLY, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Thrive Bioscience, Inc., a provider of innovative automated live cell imaging instruments and software, is pleased to announce that Todd Lewis has joined the executive management team as its Chief Commercial Officer. Todd brings over two decades of relevant experience in sales and commercial leadership within the life sciences industry, making him an excellent addition to the management team focused on driving Thrive’s growth in the market.

Continued here:
Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer

LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024. Mr. Patel will present an overview of Assertio’s business at 3:40 p.m. Eastern Time.

Read more here:
Assertio to Participate in AGP Healthcare Conference on May 21

MANKATO, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Digital Utilities Ventures, Inc. (OTC Pink: DUTV) is pleased to announce the successful acquisition of Feed Earth Now, LLC. The consummation of this transaction is a significant step forward in DUTV's mission to leverage innovative, organic products to address global fertilizer shortages through the advancement of regenerative agriculture principles. Mark K. Gaalswyk, the enterprising DUTV CEO behind this initiative, will lead the newly consolidated entity, bringing his vast experience and innovation to the forefront. Cathy Scratch, the visionary founder of Feed Earth Now, will continue in her capacity as CEO of that subsidiary. Ron Doetch, Senior Agronomist, will continue in his role as head of Research & Development for Feed Earth Now.

Here is the original post:
Digital Utilities Ventures Completes Feed Earth Now Merger - Accelerates Growth of Regenerative Agriculture Movement

WARREN, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, announces the appointment of William Keane as Vice President of Strategic Initiatives.

Excerpt from:
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the positive recommendation from the fourth scheduled meeting of the Data Monitoring Committee (“DMC”) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with MASH/NASH without modification to the current trial protocol.

Read more:
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1

Read the rest here:
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with...

CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows:

See the original post here:
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference.

Read more here:
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference

BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update.

Link:
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

Originally posted here:
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

Link:
BioSyent Declares Second Quarter 2024 Dividend

DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the appointment of Machelle Sanders to the Company’s Board of Directors. Ms. Sanders has served as North Carolina’s Secretary of Commerce since February 2021 and brings strong domain expertise from more than 30 years of operational and quality assurance roles in pharmaceutical and biotechnology companies.

Visit link:
Fortrea Appoints Machelle Sanders to Board of Directors

Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with Lenders Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with Lenders

Read the original:
Lifecore Biomedical Completes Incremental Liquidity Initiatives

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:

Read this article:
BioSyent Releases Financial Results for Q1 2024

Châtillon, France, May 16, 2024

Read the original post:
DBV Technologies Announces Results of its 2024 Combined General Meeting

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors

Read more from the original source:
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

STOCKHOLM, Sweden, May 17, 2024 (GLOBE NEWSWIRE) -- QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to the market. The GMP Certificates and Manufacturing Permits cover medicinal and investigational medicinal products for both human and veterinary use.

Originally posted here:
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.

View post:
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress